He is currently professor of immuno-oncology at the Beckman Research Institute of the City of Hope National Medical Center in Duarte, California.

[4][5][6] Kortylewski invented platform strategy for delivery of oligonucleotides, such as siRNA,[7] miRNA,[8] decoy DNA,[6][9] antisense molecules[10] and others to selected immune cells.

[1] Kortylewski began his post-graduate career in 1999 as a postdoctoral fellow in Iris Behrman’s lab in RWTH Aachen/Institute of Biochemistry chaired by Peter C. Heinrich.

[12] Later, he moved to H. Lee Moffitt Cancer Center in Tampa, Florida in USA to train with Richard Jove and Hua Yu.

Kortylewski is a co-founder of a biomedical startup company, currently under the name Duet Biotherapeutics Inc., focused on advancing CpG-STAT3 inhibitors to clinical trials for cancer immunotherapy.